Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial

Olalekan O. Oluwole, Sally W. Wade, Nathaniel J Smith, Tomas Spousta, Jenny J. Kim, Yan Zheng, Timothy Best, Markqayne Ray, Lori A. Leslie

Blood (2024) 144 (Supplement 1): 7607.

https://doi.org/10.1182/blood-2024-206879

Published: 2024

Journal Articles

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Jiasheng Wang, Shakthi Bhaskar, Babatunde Adedokun, Olalekan O. Oluwole, Leland Metheny, Amy Moskop, Caron A. Jacobson, Geoffrey Shouse, Sairah Ahmed, Armin Ghobadi, Saurabh Dahiya, Jiali Yan, Zhen-Huan Hu, Timothy Best, Jenny J. Kim, Debbie L. Mirjah, Marcelo C. Pasquini, Frederick L. Locke

Blood (2024) 144 (Supplement 1): 527.

https://doi.org/10.1182/blood-2024-209093

Published: 2024

Journal Articles

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 526.

https://doi.org/10.1182/blood-2024-199139

Published: 2024

Journal Articles

A United States (US) Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Compared to Odronextamab in Third Line or Later (3L+) Diffuse Large B-Cell Lymphoma

Frederick Locke, Bradley Kievit, Sally W. Wade, Rob Blisset, Markqayne Ray, Madhu Palivela, Timothy Best, Olalekan O. Oluwole

Blood (2024) 144 (Supplement 1): 7592.

https://doi.org/10.1182/blood-2024-199622

Published: 2024

Journal Articles

The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin's Lymphoma (NHL) - a Large, Multicenter Study

Minoo Battiwalla, Shanna Arnold Egloff, Betsy Blunk, Casey Martin, Meredith Mattlin, Katie Culos, Hil Hsu, Timothy Best, Nosha Farhadfar, Michael T. Tees, Uttam K Rao, John Mathews, Priya Amin, Rocky L. Billups, Tonya Cox, Navneet Majhail

Blood (2024) 144 (Supplement 1): 3734.

https://doi.org/10.1182/blood-2024-207777

Published: 2024

Journal Articles

A Retrospective Intra-Patient Analysis from ZUMA-5: Axicabtagene Ciloleucel (Axi-Cel) Compared with Prior Standard-of-Care Therapy in Patients with Relapsed/Refractory Follicular Lymphoma

Emmanuel Bachy, Sattva S. Neelapu, Julio C. Chavez, Ibrahim Yakoub-Agha, Christine Lui, Jacob Wulff, Harry Miao, Olga Nikolajeva, Timothy Best, Camille Linot, Caron A. Jacobson

Blood (2023) 142 (Supplement 1): 4865.

https://doi.org/10.1182/blood-2023-175055

Published: 2023

Journal Articles

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Blood (2023) 142 (Supplement 1): 2121.

https://doi.org/10.1182/blood-2023-178629

Published: 2023

Journal Articles

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment

John G. Gribben, Emmanuel Bachy, Markqayne Ray, Kathryn Krupsky, Kathleen Beusterien, Lewis Kopenhafer, Flor Mendez, Sara Beygi, Timothy Best, Graeme Ball, Kacper Perkowski, Patrick Olsen, Anik R Patel, Paola Ghione

Blood (2023) 142 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2023-190261

Published: 2023

Journal Articles

A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32

Blood (2012) 119 (2): 469–475.

https://doi.org/10.1182/blood-2011-03-343921

Published: 2012

Includes: Supplemental data

Journal Articles

Variants At 6q21 Associated with Radiation-Induced Second Malignancies After Hodgkin Lymphoma Differentially Regulate PRDM1 Expression Following Radiation Exposure

Kenan Onel, MD, PhD, Timothy Best, Shan Yu

Blood (2011) 118 (21): 431.

https://doi.org/10.1182/blood.V118.21.431.431

Published: 2011

Journal Articles

Recurrent Amplified Regions on the Long Arm of Chromosome 1 (1q) Are Associated with Disease Progression In Ph-Negative Myeloproliferative Neoplasms (MPN)

Vesna Najfeld, PhD, Joseph Tripodi, Timothy Best, Mingjiang Xu, Ronald Hoffman, MD, Kenan Onel, MD, PhD

Blood (2010) 116 (21): 3087.

https://doi.org/10.1182/blood.V116.21.3087.3087

Published: 2010

Journal Articles

A Functional Analysis of Variants Associated with Therapy-Induced Second Malignancies After Hodgkin Lymphoma Identified by a Genome-Wide Scan

Timothy Best, Andrew D Skol, Eric Gamazon, Kenan Onel, MD, PhD

Blood (2010) 116 (21): 3892.

https://doi.org/10.1182/blood.V116.21.3892.3892

Published: 2010

Journal Articles

A Meta-Analysis of Nodular Sclerosis Hodgkin Lymphoma Identifies Risk Loci at 6p21.32

Wendy Cozen, Dalin Li, Timothy Best, David J. Van Den Berg, Ph.D., Andrew Skol, Victoria K. Cortessis, Ph.D., Thomas M Mack, M.D., M.P.H., Sally L. Glaser, Ph.D., Fred Schumacher, Ph.D., Lawrence Weiss, Bharat N. Nathwani, M.D., Amie Hwang, M.P.H., Smita Bhatia, Louise C Strong, Leslie L. Robison, David V Conti, Kenan Onel, MD, PhD

Blood (2010) 116 (21): 2686.

https://doi.org/10.1182/blood.V116.21.2686.2686

Published: 2010

NARROW

Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

A United States (US) Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Compared to Odronextamab in Third Line or Later (3L+) Diffuse Large B-Cell Lymphoma

The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin's Lymphoma (NHL) - a Large, Multicenter Study

A Retrospective Intra-Patient Analysis from ZUMA-5: Axicabtagene Ciloleucel (Axi-Cel) Compared with Prior Standard-of-Care Therapy in Patients with Relapsed/Refractory Follicular Lymphoma

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment

A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32

Variants At 6q21 Associated with Radiation-Induced Second Malignancies After Hodgkin Lymphoma Differentially Regulate PRDM1 Expression Following Radiation Exposure

Recurrent Amplified Regions on the Long Arm of Chromosome 1 (1q) Are Associated with Disease Progression In Ph-Negative Myeloproliferative Neoplasms (MPN)

A Functional Analysis of Variants Associated with Therapy-Induced Second Malignancies After Hodgkin Lymphoma Identified by a Genome-Wide Scan

A Meta-Analysis of Nodular Sclerosis Hodgkin Lymphoma Identifies Risk Loci at 6p21.32

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only